Fed. Circ. Won't Revive OxyContin Anti-Abuse Patent
The Federal Circuit on Friday upheld a district court's finding that a Purdue Pharma patent for an abuse-resistant variety of OxyContin is invalid as obvious, sealing a win for generic-drug maker...To view the full article, register now.
Already a subscriber? Click here to view full article